CrispIdea equity reports provide valuable insights to investors who may be individuals and organizations involved in the world of finance and investment like private equity houses, broking firms, hedge funds, investment advisory firms, mutual funds, banks and corporations. This research report is useful for M&A, business & investment analysis to all students and researchers also.
Â
CrispIdea equity reports include basic financials, strategic analysis, competitive landscape assessments, stock performance, stock analysis and future growth potential evaluation. CrispIdea utilizes a proprietary blend of fundamental and technical analysis, offering a unique perspective. Reports present clear investment recommendations (“BUY,” “HOLD,” or “SELL”).
Â
Our established reputation and track record advocates that our research carries weight within the investment community. Do connect with us, if you are looking for customized research, equity valuation, recommendation, analysis and market recommendation for any specific company, sector and industry.
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
SPRAVATO in Neuroscience delivered 57.4% full-year growth, reaching $1.7bn, while newly acquired CAPLYTA contributed $700mn from the April 2025 Intra-Cellular Therapies acquisition, with management reiterating a greater than $5bn peak-year sales target for CAPLYTA.
Johnson & Johnson stock price surged to $248.43 as of Feb 27, 2026, from $163.77 as of Feb 27, 2025. The stock reached a 52-week high of $248.94 and its 52-week low was $141.50
 Executive Summary
• CrispIdea Forecast
– Income Statement
– Balance Sheet
– Cash Flow
– Common Size Ratio Analysis
– CrispIdea Segment Forecast
• Valuation & Historical Performance
– P/E Analysis
– CrispIdea Valuation
– Peer Comparison
– Ratio Analysis
– Economic Value-Added Analysis
– Du Pont Analysis
– CrispIdea Forecast Relative to Consensus
– Consensus Momentum
– Segment Performance
– Key Developments
– M&A Deals
• Ownership
• Stock Price Performance
• Crispidea Coverage
